Integrated microfluidic platform for utilizing aptamer-based ELISA-like assay for simultaneous detection of multiple cardiovascular clinical samples



Anirban Sinha¹, Priya Gopinathan¹, Yi-Da Chung², Shu-Chu Shieh³ and Gwo-Bin Lee^{1,2,4*} ¹Institute of Nano-Engineering and Microsystems, National Tsing Hua University, Taiwan. ² Department of Power Mechanical Engineering, National Tsing Hua University, Taiwan ³Department of Medical Laboratory Science and Biotechnology, National Cheng Kung University, Taiwan ⁴Institute of Biomedical Engineering, National Tsing Hua University, Taiwan



тни

Abstract

Cardiovascular diseases (CVDs) have been documented as one of the leading causes of deaths globally. Early detection may reduce the high risk of sudden deaths associated with CVDs. Current biomedical sensing processes vastly rely on antigen-antibody based detection processes, which have limitations in point-of-care applications. In this work, we developed an integrated microfluidic platform for the simultaneous detection up to six clinical samples using a highly specific aptamer for recognizing the CVD associated protein, cardiac troponin I (cTnI), followed by an antibody-based chemiluminescence assay in less than 30 minutes. A fully automated on-chip detection of **cTnI** was performed by using only 5 µL of clinical samples from each patient. It may serve a promising tool for CVDs monitoring and diagnosis.

Motivation and background

Initial library 72 bp ssDNA

4. Microfluidic device characterization



Figure 1: (a) The pie chart explains global cause of death in percentage. (b) Cardiovascular disease biomarkers were chosen and subsequent aptamers were screened by on-chip SELEX. (c) Two-dimensional structures of the aptamers are shown for targeting cTnI.

[Sinha et al. Biosensors and Bioelectronics, 122, pp. 104-112, 2018]





Figure 4: (a) Pumping rate of the micropump, and (b) mixing index of the open-type micromixer

5. On-chip process steps



Figure 5: Schematics of the on-chip aptamer-based ELISA-like chemiluminescence assay. (a) Biotinylated aptamer was coated onto streptavidin-coated magnetic beads; (b) Incubation of pure proteins or serums with beads and subsequent washing; (c) Transportation and mixing of primary antibody and washing; (d) Transportation of secondary antibody; (e) Finally, chemiluminescence assay with chemiluminescent HRP substrate was performed.

6. Calibration curves Risk Risk intensity (x10⁵, Luminous intensity (x10⁵ Luminous 10 0.1 0.01 0.01 0.1 Concentration (ng/ml) Concentration (ng/ml) (a)

Figure 6: (a) calibration curve using pure cTnI protein and (b) clinical serum samples of known concentrations.

Conclusions

☐ Acknowledgements



(a)

Microfluidic chip

Figure 3: (a) Schematics of the device and its parts including six open-type micromixers (#1), waste outlets (#2), six micropumps (#3), and normally-closed microvalves. (b) Exploded view of the microfluidic chip which includes air control layers (I, II), liquid control layer and a glass substrate.

(b)

This study has successfully demonstrated a new automatic microfluidic system for the measurement of cardiac troponin I, which is an important CVD biomarker, from clinical samples using an aptamer-based ELISA-like assay. With this approach, the microfluidic system can achieve rapid detection of cTnI from just 5 μ L of human serum samples without any pretreatment in 30 min. This study could replace antibodies in the conventional assay and could be useful for future point-of-care systems.

The authors would like to thank the Ministry of Science and Technology in Taiwan (MOST 106-2221-E-007-001) for funding this work. Partial financial support from Taiwan's Ministry of Education "Towards A World-class University Project" is also greatly appreciated.

Immediate Contact: Anirban Sinha Ph.D. candidate, iNEMS, NTHU. (anirban3220@gmail.com



**Prof. Gwo-Bin Lee (gwobin@pme.nthu.edu.tw)*

國立清華大學 動力機械工程學系 微流體生醫晶片實驗室 Microfluidic Biochips Lab



